Advertisement

Tumor Biology

, Volume 37, Issue 4, pp 4359–4365 | Cite as

Diagnostic and prognostic values of tissue hsa-miR-30c and hsa-miR-203 in prostate carcinoma

Original Article

Abstract

Prostate cancer (PCa) has become a prevalent malignant disease in males globally. Accumulating data suggested that hsa-microRNAs (miRNAs) could be potential biomarkers for tumor diagnosis due to their important roles in the cell cycle. This study investigated the diagnostic and prognostic values of hsa-miR-203 and hsa-miR-30c in PCa tissues. There were 44 pathologically confirmed PCa patients who were enrolled in this study. Tissue samples were collected from both tumor tissues and adjacent normal tissues. RNA was extracted and the expression levels of hsa-miR-203 and hsa-miR-30c in tumor and normal tissues were compared. The receiver operating characteristic (ROC) curves were plotted to evaluate the reliability of hsa-miR-203 and hsa-miR-30c in detecting PCa. All subjects in this study were followed up by 36 months, and the Kaplan-Meier method was conducted to investigate the survival status of PCa patients. The average relative expressions of hsa-miR-203 and hsa-miR-30c in tumor tissues were significantly different from those in adjacent normal tissues (P < 0.001), and the predictive power of the two hsa-miRNAs for PCa prognosis was reliable. Besides that, the average survival times of low-hsa-miR-30c and high-hsa-miR-203 groups were significantly lower than those of the corresponding groups with the log-rank P of 0.015 and 0.023, respectively. In summary, our study suggested that both hsa-miR-203 and hsa-miR-30c are potential biomarkers for detection and prognosis of PCa.

Keywords

Prostate cancer MicroRNAs Biological markers Diagnosis Prognosis 

Notes

Acknowledgments

This study is supported by the National Science Foundation of China (NSFC 81570053), Shanghai Science and Technology Commission Foundation of Key Medical Research (034119868 and 09411951600), and Research Foundation of Shanghai Municipal Health Bureau (20134034).

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer J Int du cancer. 2010;127:118–26.CrossRefGoogle Scholar
  2. 2.
    Casanova-Salas I, Rubio-Briones J, Calatrava A, Mancarella C, Masia E, Casanova J, Fernandez-Serra A, Rubio L, Ramirez-Backhaus M, Arminan A, Dominguez-Escrig J, Martinez F, Garcia-Casado Z, Scotlandi K, Vicent MJ, Lopez-Guerrero JA. Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. J Urol 2014Google Scholar
  3. 3.
    Peyromaure EM, Mao K, Sun Y, Xia S, Jiang N, Zhang S, et al. A comparative study of prostate cancer detection and management in China and in France. Can J Urol. 2009;16:4472–7.PubMedGoogle Scholar
  4. 4.
    Roberts WW, Bergstralh EJ, Blute ML, Slezak JM, Carducci M, Han M, et al. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology. 2001;57:1033–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Xiong SW, Lin TX, Xu KW, Dong W, Ling XH, Jiang FN, et al. MicroRNA-335 acts as a candidate tumor suppressor in prostate cancer. Pathol Oncol Res. 2013;19:529–37.CrossRefPubMedGoogle Scholar
  6. 6.
    Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, et al. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics. 2010;3:8.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Catalona WJ, Partin AW, Finlay JA, Chan DW, Rittenhouse HG, Wolfert RL, et al. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/ml and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology. 1999;54:220–4.CrossRefPubMedGoogle Scholar
  8. 8.
    Emiliozzi P, Longhi S, Scarpone P, Pansadoro A, DePaula F, Pansadoro V. The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. J Urol. 2001;166:845–50.CrossRefPubMedGoogle Scholar
  9. 9.
    Roehl KA, Antenor JA, Catalona WJ. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. range. J Urol. 2002;168:922–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007;13:7053–8.CrossRefPubMedGoogle Scholar
  11. 11.
    de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Gonzales JC, Fink LM, Goodman Jr OB, Symanowski JT, Vogelzang NJ, Ward DC. Comparison of circulating microRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer. 2011;9:39–45.CrossRefPubMedGoogle Scholar
  13. 13.
    Mavridis K, Stravodimos K, Scorilas A. Downregulation and prognostic performance of microRNA 224 expression in prostate cancer. Clin Chem. 2013;59:261–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Loeb S, Partin AW. Review of the literature: PCA3 for prostate cancer risk assessment and prognostication. Rev Urol. 2011;13:e191–195.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Yaman Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol. 2011;32:583–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Haj-Ahmad TA, Abdalla MA, Haj-Ahmad Y. Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J Cancer Educ. 2014;5:182–91.CrossRefGoogle Scholar
  17. 17.
    Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997–1006.CrossRefPubMedGoogle Scholar
  18. 18.
    Casanova-Salas I, Rubio-Briones J, Fernandez-Serra A, Lopez-Guerrero JA. MiRNAs as biomarkers in prostate cancer. Clin Transl Oncol. 2012;14:803–11.CrossRefPubMedGoogle Scholar
  19. 19.
    Deng Y, Huang Z, Xu Y, Jin J, Zhuo W, Zhang C, et al. MiR-215 modulates gastric cancer cell proliferation by targeting RB1. Cancer Lett. 2014;342:27–35.CrossRefPubMedGoogle Scholar
  20. 20.
    Yuxia M, Zhennan T, Wei Z. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J Cancer Res Clin Oncol. 2012;138:2045–50.CrossRefPubMedGoogle Scholar
  21. 21.
    Mar-Aguilar F, Luna-Aguirre CM, Moreno-Rocha JC, Araiza-Chavez J, Trevino V, Rodriguez-Padilla C, et al. Differential expression of miR-21, miR-125b and miR-191 in breast cancer tissue. Asia Pac J Clin Oncol. 2013;9:53–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Guo F, Tian J, Lin Y, Jin Y, Wang L, Cui M. Serum microrna-92 expression in patients with ovarian epithelial carcinoma. J Int Med Res. 2013;41:1456–61.CrossRefPubMedGoogle Scholar
  23. 23.
    Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, et al. Micro-rna profiling in kidney and bladder cancers. Urol Oncol. 2007;25:387–92.CrossRefPubMedGoogle Scholar
  24. 24.
    Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One. 2009;4, e6229.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Saini S, Majid S, Dahiya R. Diet, microRNAs and prostate cancer. Pharm Res. 2010;27:1014–26.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    He HC, Zhu JG, Chen XB, Chen SM, Han ZD, Dai QS, et al. MicroRNA-23b downregulates peroxiredoxin III in human prostate cancer. FEBS Lett. 2012;586:2451–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Viticchie G, Lena AM, Latina A, Formosa A, Gregersen LH, Lund AH, et al. MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle. 2011;10:1121–31.CrossRefPubMedGoogle Scholar
  28. 28.
    Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stoppler H, et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 2011;71:550–60.CrossRefPubMedGoogle Scholar
  29. 29.
    Ling XH, Han ZD, Xia D, He HC, Jiang FN, Lin ZY, et al. MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer. Mol Biol Rep. 2014;41:2779–88.CrossRefPubMedGoogle Scholar
  30. 30.
    Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol. 2011;45:355–60.CrossRefPubMedGoogle Scholar
  31. 31.
    Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Benaich N, Woodhouse S, Goldie SJ, Mishra A, Quist SR, Watt FM. Rewiring of an epithelial differentiation factor, miR-203, to inhibit human squamous cell carcinoma metastasis. Cell Rep. 2014;9:104–17.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Noguchi S, Kumazaki M, Mori T, Baba K, Okuda M, Mizuno T, Akao Y. Analysis of microrna-203 function in CREB/MITF/RAB27a pathway: comparison between canine and human melanoma cells. Vet Comp Oncol 2014Google Scholar
  34. 34.
    Boll K, Reiche K, Kasack K, Morbt N, Kretzschmar AK, Tomm JM, et al. MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene. 2013;32:277–85.CrossRefPubMedGoogle Scholar
  35. 35.
    Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009;11:1487–95.CrossRefPubMedGoogle Scholar
  36. 36.
    Fang Y, Shen H, Cao Y, Li H, Qin R, Chen Q, et al. Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells. Braz J Med Biol Res. 2014;47:60–9.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Kong X, Xu X, Yan Y, Guo F, Li J, Hu Y, et al. Estrogen regulates the tumour suppressor miRNA-30c and its target gene, MTA-1, in endometrial cancer. PLoS One. 2014;9, e90810.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Ren Q, Liang J, Wei J, Basturk O, Wang J, Daniels G, et al. Epithelial and stromal expression of miRNAs during prostate cancer progression. Am J Transl Res. 2014;6:329–39.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Kim JH, Lee JM, Nam HJ, Choi HJ, Yang JW, Lee JS, et al. SUMOylation of pontin chromatin-remodeling complex reveals a signal integration code in prostate cancer cells. Proc Natl Acad Sci U S A. 2007;104:20793–8.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Wang XS, Shankar S, Dhanasekaran SM, Ateeq B, Sasaki AT, Jing X, et al. Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discovery. 2011;1:35–43.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Wang H, Fan L, Wei J, Weng Y, Zhou L, Shi Y, et al. Akt mediates metastasis-associated gene 1 (MTA1) regulating the expression of e-cadherin and promoting the invasiveness of prostate cancer cells. PLoS One. 2012;7, e46888.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Kao CJ, Martiniez A, Shi XB, Yang J, Evans CP, Dobi A, et al. MiR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene. 2014;33:2495–503.CrossRefPubMedGoogle Scholar
  43. 43.
    Zhang K, Dai L, Zhang B, Xu X, Shi J, Fu L, Chen X, Li J, Bai Y. MiR-203 is a direct transcriptional target of E2F1 and causes G1 arrest in esophageal cancer cells. J Cell Physiol 2014Google Scholar
  44. 44.
    Zhong K, Chen K, Han L, Li B. MicroRNA-30b/c inhibits non-small cell lung cancer cell proliferation by targeting rab18. BMC Cancer. 2014;14:703.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of PathologyTongji Hospital, Tongji University School of MedicineShanghaiChina
  2. 2.Department of PathologyLabway Clinical Laboratory Shanghai LtdShanghaiChina

Personalised recommendations